China’s Covid-19 vaccine candidate triggers an antibody response, early-stage results show...

China’s Covid-19 vaccine candidate triggers an antibody response, early-stage results show...
China’s Covid-19 vaccine candidate triggers an antibody response, early-stage results show...
BEIJING: China’s Covid-19 vaccine candidate triggers an antibody response to the coronavirus, results published Thursday in The Lancet Infectious Diseases Journal show. These results were the result of a small randomized early-stage clinical trial of the Chinese Covid-19 vaccine candidate based on the inactivated whole SARS-CoV-2 virus.

Trials for this vaccine candidate were conducted in China between April 29 and July 30 this year. Researchers from several institutions were involved, including the Beijing Institute of Biological Products.

According to a report by Reuters news agency, the results of this early study indicated that the vaccine candidate elicited antibody responses in all recipients within 42 days. The report cites results published in the Lancet Infectious Diseases Journal to confirm that the vaccine candidate is safe as none of the participants experienced any serious side effects during the studies.

More than 600 healthy volunteers between the ages of 18 and 80 participated in these early studies for China’s vaccine candidate Covid-19.

The research team reiterated that the goal of early-stage studies is to assess the safety of the vaccine and the immune response it creates. The researchers reiterated that this is insufficient to confirm whether this vaccine candidate is sufficient to protect recipients from Covid-19.

However, the researchers said the results of these early-stage clinical trials will prove useful during Phase 3 clinical trials of China’s Covid-19 vaccine candidate.

China has four Covid-19 vaccines in the final stages of clinical trials, at least three of which have already been made available to essential workers as part of an emergency program launched in July.

Data released by the World Health Organization (WHO) suggests there are more than 40 Covid-19 vaccine candidates in clinical trials. The novel coronavirus infected 3,95,88,293 people worldwide and claimed 11,08,576 lives in the process.

KEYWORDS:
COVID19 Vaccination,
EARLY DATE,
RESULTS,
SARS-COV-2,
RANDOMIZED CLINICAL STUDY,
CHINESE COVID-19 Vaccine,
BEIJING INSTITUTE FOR ORGANIC PRODUCTS,
REUTERS,
LANCET INFECTIOUS DISEASES JOURNAL,
IMMUNE REACTION,
LANZETTE,
CLINICAL TRIALS,
WORLD HEALTH ORGANIZATION

These were the details of the news China’s Covid-19 vaccine candidate triggers an antibody response, early-stage results show... for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at de24.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV NHS staff “want to get Covid vaccine in WEEKS as government...
NEXT Nuneaton Hospital at the center of coronavirus vaccine revelation for all...